Coronary artery disease (CAD) is the single largest killer of Americans, producing acute myocardial infarctions (AMIs) and subsequent heart failure (HF). The dearth of mechanistic studies and the recognition of unmet treatment needs of patients with cardiovascular disease in the United States led NHLBI to establish the Cardiovascular Cell Therapy Research Network (CCTRN). The Network was to build upon contemporary (2006) findings of the cell therapy basic science community, translating newly acquired information from preclinical and pilot data to the clinical setting in the Phase l/ll study paradigm. The current CCTRN-1 consists of the Cleveland Clinic Foundation (CCF), the University of Florida (UFL), the Minneapolis Heart Institute Foundation (MHIF), the Texas Heart Institute (THI), and Vanderbilt University (VU);as well as five cell processing laboratories, one at each main center;seven satellite clinical centers (University Hospitals, DeBakey Veterans Administration, Pepin Heart Hospital, St. Paul Heart Clinic, Metropolitan Cardiology Consultants, the University of Minnesota, and the Mayo Clinic);a cell processing quality control laboratory (CP-QCL);five core laboratories;the NHLBI Project Office;and the DCC which provides Network trial management and data analyses. The University of Texas School of Public Health (UTSPH) Coordinating Center for Clinical Trials (CCCT) has served as the Data Coordinating Center (DCC) for the CCTRN since the Network's inception in January 2007. The personnel have been, and continue to be, committed to CCTRN's success. The DCC works closely with NHLBI and the Steering Committee chair in decision making and the discharge of critical leadership responsibilities. In CCTRN-2, the DCC will continue to assist the Network in research endeavors by providing support in the following areas, protocol development, regulatory affairs, statistical leadership, financial management, meeting logistics, data/web capability, quality control, as well as outreach and dissemination. The DCC will also strive to identify opportunities for expanded growth and collaboration with other Networks, industry partners, and other respected Investigators in the field of cell therapy.

Public Health Relevance

The CCTRN is to promote evaluation of novel cell-based treatment strategies for individuals with cardiovascular disease. The Network provides support to maintain an infrastructure to develop, coordinate, and conduct multiple collaborative clinical trials designed to improve cardiovasular disease outcomes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1HL087318-08
Application #
8610938
Study Section
Special Emphasis Panel (ZHL1-CSR-O (F1))
Program Officer
Ebert, Ray F
Project Start
2007-01-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
8
Fiscal Year
2014
Total Cost
$8,100,818
Indirect Cost
$1,200,451
Name
University of Texas Health Science Center Houston
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Shahrivari, Mahan; Wise, Elizabeth; Resende, Micheline et al. (2017) Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1?- and IL-6-Related Impairment of Bone Marrow Function. Circ Res 120:1947-1957
Jokerst, Jesse V; Cauwenberghs, Nicholas; Kuznetsova, Tatiana et al. (2017) Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Sci Rep 7:4419
Contreras, Ariadna; Orozco, Aaron F; Resende, Micheline et al. (2017) Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. Basic Res Cardiol 112:3
Perin, Emerson C; Murphy, Michael P; March, Keith L et al. (2017) Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation 135:1417-1428
Traverse, Jay H; Henry, Timothy D; Pepine, Carl J et al. (2017) The TIME Trial - Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. Circ Res :
Traverse, Jay H (2017) Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy? Circ Res 120:256-258
Simari, Robert D (2017) Forging the Fate of Cellular Therapies for Cardiovascular Disease. Circ Res 120:1871-1873
Venkatesh, Bharath Ambale; Nauffal, Victor; Noda, Chikara et al. (2017) Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network ""Patients with Intermittent Claudication Injected with ALDH Bright Cells" Am Heart J 183:24-34
Gyöngyösi, Mariann; Wojakowski, Wojciech; Navarese, Eliano P et al. (2016) Meta-Analyses of Human Cell-Based Cardiac Regeneration Therapies: Controversies in Meta-Analyses Results on Cardiac Cell-Based Regenerative Studies. Circ Res 118:1254-63
Golpanian, Samuel; Schulman, Ivonne H; Ebert, Ray F et al. (2016) Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Transl Med 5:186-91

Showing the most recent 10 out of 49 publications